The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online

VJ OncologyFollow

The Video Journal of Oncology is dedicated to providing trusted information to improve knowledge, understanding and awareness of cancer. Intended for HCPs only.

VJ Oncology
VJOncologyVJ Oncology@VJOncology·
July 6, 2022

📢2 days to go until the #BTOGSummerMeeting where #LungCancer experts will share the latest updates in the field!

Register now ➡️http://ow.ly/TIQC50JCTgr

Visit http://VJOncology.com for exclusive interviews from the event!

👉https://www.vjoncology.com/event/btog-2022/

#LCsm #NSCLC #Mesothelioma

Reply on Twitter 1544683691183579137Retweet on Twitter 1544683691183579137Like on Twitter 1544683691183579137Twitter 1544683691183579137
VJOncologyVJ Oncology@VJOncology·
July 6, 2022

🎥 Kendall Morrison of @taelifesciences talks on treating glioblastoma with boron neutron capture therapy

Watch: 👉http://ow.ly/ULLC50JO0ym👈

#BNOS2022 @BNOSofficial #BTSM

Reply on Twitter 1544592376169119745Retweet on Twitter 1544592376169119745Like on Twitter 15445923761691197451Twitter 1544592376169119745
VJOncologyVJ Oncology@VJOncology·
July 5, 2022

🎥 @HamounRozati of @imperialcollege talks on assessing stereotactic radiotherapy in patients with high numbers of brain metastases

Watch: 👉http://ow.ly/ZVlE50JO0rN👈

#BNOS2022 @BNOSofficial #BTSM #RadOnc

Reply on Twitter 1544351225315049474Retweet on Twitter 1544351225315049474Like on Twitter 1544351225315049474Twitter 1544351225315049474
VJOncologyVJ Oncology@VJOncology·
July 5, 2022

🎥 John Strickler of @DukeCancer talks on MOUNTAINEER: Tucatinib plus trastuzumab for HER2+ metastatic colorectal cancer

Watch: 👉http://ow.ly/FB9A50JO0ps👈

@myESMO @ESMOWorldGI #WCGIC22 #CRCsm #ColorectalCancer

Reply on Twitter 1544229950923874304Retweet on Twitter 1544229950923874304Like on Twitter 15442299509238743041Twitter 1544229950923874304
Retweet on TwitterVJ Oncology Retweeted
tompowles1Tom Powles@tompowles1·
July 4, 2022

longer follow up (3 years) continues to show ctDNA is strongly associated with relapse (HR=6) and a 40% ⬇️ risk of death with atezo in adjuvant UC. There’s a strong rationale for circulating rather than tissue biomarkers here. Imvigor011 (randomised III) tests this prospectively

4
Reply on Twitter 1543998628007747584Retweet on Twitter 154399862800774758460Like on Twitter 1543998628007747584146Twitter 1543998628007747584
Load More

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

VJ OncologyFollow

The Video Journal of Oncology is dedicated to providing trusted information to improve knowledge, understanding and awareness of cancer. Intended for HCPs only.

VJ Oncology
VJOncologyVJ Oncology@VJOncology·
July 6, 2022

📢2 days to go until the #BTOGSummerMeeting where #LungCancer experts will share the latest updates in the field!

Register now ➡️http://ow.ly/TIQC50JCTgr

Visit http://VJOncology.com for exclusive interviews from the event!

👉https://www.vjoncology.com/event/btog-2022/

#LCsm #NSCLC #Mesothelioma

Reply on Twitter 1544683691183579137Retweet on Twitter 1544683691183579137Like on Twitter 1544683691183579137Twitter 1544683691183579137
VJOncologyVJ Oncology@VJOncology·
July 6, 2022

🎥 Kendall Morrison of @taelifesciences talks on treating glioblastoma with boron neutron capture therapy

Watch: 👉http://ow.ly/ULLC50JO0ym👈

#BNOS2022 @BNOSofficial #BTSM

Reply on Twitter 1544592376169119745Retweet on Twitter 1544592376169119745Like on Twitter 15445923761691197451Twitter 1544592376169119745
VJOncologyVJ Oncology@VJOncology·
July 5, 2022

🎥 @HamounRozati of @imperialcollege talks on assessing stereotactic radiotherapy in patients with high numbers of brain metastases

Watch: 👉http://ow.ly/ZVlE50JO0rN👈

#BNOS2022 @BNOSofficial #BTSM #RadOnc

Reply on Twitter 1544351225315049474Retweet on Twitter 1544351225315049474Like on Twitter 1544351225315049474Twitter 1544351225315049474
VJOncologyVJ Oncology@VJOncology·
July 5, 2022

🎥 John Strickler of @DukeCancer talks on MOUNTAINEER: Tucatinib plus trastuzumab for HER2+ metastatic colorectal cancer

Watch: 👉http://ow.ly/FB9A50JO0ps👈

@myESMO @ESMOWorldGI #WCGIC22 #CRCsm #ColorectalCancer

Reply on Twitter 1544229950923874304Retweet on Twitter 1544229950923874304Like on Twitter 15442299509238743041Twitter 1544229950923874304
Retweet on TwitterVJ Oncology Retweeted
tompowles1Tom Powles@tompowles1·
July 4, 2022

longer follow up (3 years) continues to show ctDNA is strongly associated with relapse (HR=6) and a 40% ⬇️ risk of death with atezo in adjuvant UC. There’s a strong rationale for circulating rather than tissue biomarkers here. Imvigor011 (randomised III) tests this prospectively

4
Reply on Twitter 1543998628007747584Retweet on Twitter 154399862800774758460Like on Twitter 1543998628007747584146Twitter 1543998628007747584
Load More

Late-Breaking Abstracts at ASCO 2022!

View all
1:28
PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC
Takayuki Yoshino • 5 Jun 2022
2:18
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
1:22
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
Alexander Spira • 3 Jun 2022
5:11
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
Hope Rugo • 5 Jun 2022

Latest videos from ASCO 2022

View all
1:17
MK-0482-001: evaluating MK-0482 plus pembrolizumab in patients with advanced solid tumors
Andre Goy • 5 Jun 2022
4:53
Phase I trial of mRNA neoantigen vaccines for pancreatic cancer
Vinod P. Balachandran • 16 Jun 2022
3:17
Development of individualized mRNA neoantigen vaccines for pancreatic cancer
Vinod Balachandran • 16 Jun 2022
1:31
Potential of immunotherapy for pancreatic cancer
Vinod P. Balachandran • 16 Jun 2022

Breast Cancer at ASCO 2022

View all
4:28
Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancer
Thomas Meyskens • 30 May 2022
3:01
Assessing elacestrant in ctDNA-positive patients with ER+ breast cancer
Thomas Meyskens • 30 May 2022
2:35
AMEERA-6: Amcenestrant, a novel SERD, in HR+ breast cancer
Thomas Meyskens • 30 May 2022
1:08
DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer
Thomas Meyskens • 30 May 2022

GU at ASCO 2022

View all
1:25
Phase II study of neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with MIBC
Jonathan E. Rosenberg • 5 Jun 2022
2:04
Areas of unmet need in metastatic urothelial carcinoma
Robert Jones • 4 Jun 2022
1:10
ASCO 2022: genitourinary cancer highlights
Robert Jones • 4 Jun 2022
1:11
RECIP: a novel framework for treatment response evaluation using PSMA-PET/CT in patients with mCRPC
Andrei Gafita • 4 Jun 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals